Today's Low
₹ 983.00
Today's High
₹ 1,005.00
52 Weeks Low
₹ 502.00
52 Weeks High
₹ 778.90
Lower
₹ 796.85
Upper
₹ 1,195.25
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3,000.3 | 2,486.7 | 2,344.8 | 2,325.6 | 2,347.2 | 2,130.7 | 1,087.3 | 837.0 | 483.0 | 368.1 | 330.5 | 292.8 | 247.0 |
Total Non-Current Assets | 2,657.1 | 2,622.4 | 2,447.1 | 2,262.2 | 1,955.9 | 1,584.4 | 1,230.3 | 984.7 | 901.1 | 827.6 | 749.9 | 612.4 | 460.4 |
Total Assets | 5,657.4 | 5,109.1 | 4,791.9 | 4,587.8 | 4,303.1 | 3,715.1 | 2,317.6 | 1,821.7 | 1,384.1 | 1,195.7 | 1,080.4 | 905.2 | 707.3 |
Total Current Liabilities | 683.1 | 710.4 | 525.6 | 685.3 | 728.7 | 592.0 | 626.5 | 493.1 | 413.7 | 312.3 | 344.9 | 259.4 | 193.4 |
Total Non-Current Liabilities | 100.5 | 135.1 | 142.9 | 117.8 | 83.4 | 47.1 | 37.7 | 28.0 | 119.2 | 150.7 | 191.5 | 171.3 | 160.4 |
Shareholder's Funds | 4,873.8 | 4,263.6 | 4,121.6 | 3,773.5 | 3,489.0 | 3,072.2 | 1,649.3 | 1,295.7 | 846.1 | 725.9 | 533.5 | 473.6 | 352.4 |
Total Liabilities | 5,657.4 | 5,109.1 | 4,791.9 | 4,587.8 | 4,303.1 | 3,715.1 | 2,317.6 | 1,821.7 | 1,384.1 | 1,195.7 | 1,080.4 | 905.2 | 707.3 |
The Industry Price to BV stands at 6.03, vs the Price to BV of 3.25, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 2.63, which results in a Positive aspect.
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 0.08, which results in a Positive aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 3.39, which results in a Positive aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 2,707.1 | 1,944.8 | 2,052.1 | 1,915.0 | 2,094.5 | 2,184.8 | 2,020.2 | 1,042.3 | 825.3 | 738.9 | 660.5 | 523.7 | 459.7 |
Total Expenditure | 1,795.4 | 1,681.3 | 1,448.3 | 1,332.4 | 1,299.7 | 1,256.4 | 1,336.8 | 776.7 | 619.7 | 559.6 | 510.6 | 414.4 | 369.1 |
Operating Profit(Excl OI) | 1,040.2 | 362.5 | 709.8 | 690.0 | 925.0 | 968.8 | 697.3 | 275.2 | 220.5 | 196.0 | 162.3 | 118.5 | 95.2 |
Add: Other Income | 128.5 | 99.0 | 106.0 | 107.4 | 130.2 | 40.4 | 13.9 | 9.6 | 14.9 | 16.7 | 12.4 | 9.1 | 4.6 |
Operating Profit | 1,040.2 | 362.5 | 709.8 | 690.0 | 925.0 | 968.8 | 697.3 | 275.2 | 220.5 | 196.0 | 162.3 | 118.5 | 95.2 |
Less: Interest | 14.5 | 17.7 | 13.3 | 21.5 | 19.3 | 15.4 | 18.5 | 22.9 | 31.7 | 36.6 | 26.3 | 23.0 | 14.2 |
PBDT | 1,025.7 | 344.8 | 696.5 | 668.5 | 905.7 | 953.4 | 678.8 | 252.3 | 188.8 | 159.4 | 136.0 | 95.5 | 81.0 |
Less: Depreciation Amortization | 163.8 | 142.6 | 116.9 | 99.8 | 81.0 | 66.2 | 54.4 | 50.8 | 47.3 | 30.4 | 22.1 | 15.9 | 15.9 |
PBT & Exceptional Items | 861.9 | 202.2 | 579.6 | 568.7 | 824.7 | 887.2 | 624.4 | 201.5 | 141.6 | 129.0 | 113.9 | 79.5 | 65.1 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -15.1 | 0.0 | -11.6 | 0.0 | 0.0 |
Profit Before Tax | 861.9 | 202.2 | 579.6 | 568.7 | 824.7 | 887.2 | 624.4 | 201.5 | 126.5 | 129.0 | 102.3 | 79.5 | 65.1 |
Less: Taxation | 146.6 | 32.2 | 137.2 | 110.6 | 182.3 | 192.0 | 139.5 | 47.9 | 1.5 | 30.9 | 36.4 | 21.1 | 13.2 |
Profit After Tax | 715.3 | 170.0 | 442.4 | 458.1 | 642.4 | 695.2 | 484.9 | 153.6 | 124.9 | 98.1 | 65.9 | 58.5 | 51.9 |
Earnings Per Share | 3.9 | 0.9 | 2.4 | 2.5 | 3.5 | 3.8 | 2.8 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.55, which results in a Negative aspect.
The Industry PAT Margin stands at 9.75, vs the PAT Margin of 22.26, which results in a Positive aspect.
The Industry PAT Growth stands at 32.19, vs the PAT Growth of -28.69, which results in a Negative aspect.
The Industry PE Ratio stands at 42.56, vs the PE Ratio of 14.00, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 861.9 | 202.2 | 579.6 | 568.7 | 824.7 | 887.2 | 624.4 | 208.6 | 134.2 | 129.0 | 102.3 | 79.5 | 65.1 |
Tax Paid | -177.5 | -48.2 | -130.0 | -107.8 | -178.8 | -204.6 | -125.8 | -46.2 | -23.7 | -34.6 | -22.6 | -23.6 | -18.5 |
Adjustment | 102.0 | 123.9 | 62.1 | 54.0 | 14.3 | 75.6 | 100.2 | 90.5 | 68.1 | 65.7 | 48.9 | 37.0 | 38.9 |
Changes In Working Capital | 861.9 | 202.2 | 579.6 | 568.7 | 824.7 | 887.2 | 624.4 | 208.6 | 134.2 | 129.0 | 102.3 | 79.5 | 65.1 |
Cash Flow after changes in Working Capital | 1,026.6 | 94.7 | 428.8 | 525.1 | 847.6 | 668.2 | 471.6 | 158.4 | 116.4 | 178.6 | 83.8 | 88.5 | 55.5 |
Cash Flow from Operating Activities | 849.1 | 46.5 | 298.8 | 417.3 | 668.8 | 463.6 | 345.8 | 112.2 | 92.7 | 144.0 | 61.2 | 64.9 | 37.0 |
Cash Flow from Investing Activities | -477.1 | -5.3 | -103.3 | -167.0 | -612.2 | -1,115.5 | -299.4 | -175.5 | -114.8 | -108.9 | -107.1 | -126.9 | -88.8 |
Cash Flow from Financing Activities | -363.0 | 34.8 | -185.7 | -250.8 | -50.9 | 650.9 | -47.7 | 154.0 | 29.1 | -35.3 | 26.3 | 62.8 | 77.1 |
Net Cash Inflow / Outflow | 9.0 | 76.0 | 9.8 | -0.5 | 5.7 | -1.0 | -1.3 | 90.7 | 7.0 | -0.2 | -19.6 | 0.8 | 25.3 |
Opening Cash & Cash Equivalents | 111.1 | 25.8 | 19.8 | 28.3 | 21.7 | 23.5 | 24.2 | -164.1 | 10.2 | 10.0 | 34.6 | 31.7 | 6.5 |
Closing Cash & Cash Equivalent | 131.9 | 111.1 | 25.8 | 19.8 | 28.3 | 21.7 | 23.5 | -74.2 | 12.4 | 10.2 | 10.0 | 34.6 | 31.7 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of 90.58, which results in a Positive aspect.
The Industry PCF RATIO stands at 24.29, vs the PCF RATIO of 22.08, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 7,586.0 | 10,314.0 | 11,405.0 | 8,979.0 | 4,925.0 | 4,321.0 | 8,846.0 | 5,968.0 | 5,605.0 | 3,772.0 | 4,103.0 | 3,313.0 | 3,552.0 | 8,022.0 | 5,634.0 | 4,548.0 |
Total Income | 7,956.0 | 10,608.0 | 11,602.0 | 9,269.0 | 5,133.0 | 4,526.0 | 9,189.0 | 6,106.0 | 5,907.0 | 4,152.0 | 4,273.0 | 3,597.0 | 3,860.0 | 8,279.0 | 5,821.0 | 4,772.0 |
Total Expenditure | 4,905.0 | 5,734.0 | 6,125.0 | 5,588.0 | 3,866.0 | 3,368.0 | 4,893.0 | 6,154.0 | 4,587.0 | 3,067.0 | 3,005.0 | 2,551.0 | 2,727.0 | 5,258.0 | 3,923.0 | 3,265.0 |
PBIDT (Excl OI) | 2,681.0 | 4,580.0 | 5,280.0 | 3,391.0 | 1,059.0 | 953.0 | 3,953.0 | -186.0 | 1,018.0 | 705.0 | 1,098.0 | 762.0 | 825.0 | 2,764.0 | 1,711.0 | 1,283.0 |
Other Income | 370.0 | 294.0 | 197.0 | 290.0 | 208.0 | 205.0 | 343.0 | 138.0 | 302.0 | 380.0 | 170.0 | 284.0 | 308.0 | 257.0 | 187.0 | 224.0 |
Operating Profit | 3,051.0 | 4,874.0 | 5,477.0 | 3,681.0 | 1,267.0 | 1,158.0 | 4,296.0 | -48.0 | 1,320.0 | 1,085.0 | 1,268.0 | 1,046.0 | 1,133.0 | 3,021.0 | 1,898.0 | 1,507.0 |
Interest | 46.0 | 42.0 | 42.0 | 27.0 | 38.0 | 38.0 | 42.0 | 67.0 | 50.0 | 40.0 | 20.0 | 35.0 | 34.0 | 27.0 | 37.0 | 35.0 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 3,005.0 | 4,832.0 | 5,435.0 | 3,654.0 | 1,229.0 | 1,120.0 | 4,254.0 | -115.0 | 1,270.0 | 1,045.0 | 1,248.0 | 1,011.0 | 1,099.0 | 2,994.0 | 1,861.0 | 1,472.0 |
Depreciation | 442.0 | 436.0 | 435.0 | 410.0 | 415.0 | 417.0 | 396.0 | 381.0 | 360.0 | 347.0 | 338.0 | 304.0 | 298.0 | 287.0 | 280.0 | 305.0 |
Profit Before Tax | 2,563.0 | 4,396.0 | 5,000.0 | 3,244.0 | 814.0 | 703.0 | 3,858.0 | -496.0 | 910.0 | 698.0 | 910.0 | 707.0 | 801.0 | 2,707.0 | 1,581.0 | 1,167.0 |
Tax | 436.0 | 706.0 | 797.0 | 486.0 | 191.0 | 135.0 | 654.0 | 9.0 | 106.0 | 47.0 | 160.0 | 177.0 | 167.0 | 668.0 | 360.0 | 235.0 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 2,127.0 | 3,690.0 | 4,203.0 | 2,758.0 | 623.0 | 568.0 | 3,204.0 | -505.0 | 804.0 | 651.0 | 750.0 | 530.0 | 634.0 | 2,039.0 | 1,221.0 | 932.0 |
Net Profit | 2,127.0 | 3,690.0 | 4,203.0 | 2,758.0 | 623.0 | 568.0 | 3,204.0 | -505.0 | 804.0 | 651.0 | 750.0 | 530.0 | 634.0 | 2,039.0 | 1,221.0 | 932.0 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 358.0 | 358.0 | 358.0 | 365.0 | 365.0 | 365.0 | 365.0 | 365.0 | 365.0 | 365.0 | 365.0 | 365.0 | 364.0 | 364.0 | 364.0 | 364.0 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 11.9 | 20.6 | 23.3 | 15.1 | 3.4 | 3.1 | 17.6 | -2.8 | 4.4 | 3.6 | 4.1 | 2.9 | 3.4 | 11.1 | 6.7 | 5.2 |
Operating Profit Margin | 40.2 | 47.3 | 48.0 | 41.0 | 25.7 | 26.8 | 48.6 | -0.8 | 23.6 | 28.8 | 30.9 | 31.6 | 31.9 | 37.7 | 33.7 | 33.1 |
Net Profit Margin | 28.0 | 35.8 | 36.9 | 30.7 | 12.6 | 13.1 | 36.2 | -8.5 | 14.3 | 17.3 | 18.3 | 16.0 | 17.8 | 25.4 | 21.7 | 20.5 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of -8.57, which results in a Negative aspect.
The Industry Mcap Growth stands at 19.69, vs the Mcap Growth of -11.78, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 1,043.40 | 1,062.70 | 1,011.50 |
R3 | 1,030.60 | 1,032.40 | 1,005.45 |
R2 | 1,017.80 | 1,018.70 | 1,003.43 |
R1 | 1,008.60 | 1,010.40 | 1,001.42 |
Pivot | 995.80 | 996.70 | 995.80 |
S1 | 986.60 | 988.40 | 997.38 |
S2 | 973.80 | 974.70 | 995.37 |
S3 | 964.60 | 966.40 | 993.35 |
S4 | 955.40 | 930.70 | 987.30 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
89.62
Bearish
RSI
56.56
Neutral
ROC
0.01
Bullish
UltimateOscillator
49.59
Neutral
Williams Indicator
-41.28
Neutral
CCI Indicator
50.25
Neutral
MACD
-2,204.13
Bearish
Stochastic Indicator
57.51
Neutral
ATR
33.10
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|---|---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|---|---|---|
26-02-2024 | 1.25 | 62.5 | Interim |
24-11-2023 | 1.25 | 62.5 | Interim |
22-08-2023 | 7.00 | 350 | Interim |
21-02-2023 | 1.25 | 62.5 | Interim |
21-11-2022 | 0.75 | 37.5 | Interim |
19-08-2022 | 3.50 | 175 | Interim |
24-02-2022 | 2.00 | 100 | Interim |
23-11-2021 | 0.50 | 25 | Interim |
24-08-2021 | 2.00 | 100 | Interim |
Date Of Conduct | Board Meeting Details |
---|---|
14-02-2024 | Interim Dividend & Quarterly Results |
14-11-2023 | Quarterly Results & Interim Dividend |
09-08-2023 | Quarterly Results & Interim Dividend |
29-05-2023 | Audited Results |
08-03-2023 | Buy Back of Shares |
09-02-2023 | Quarterly Results & Interim Dividend |
10-11-2022 | Quarterly Results & Second Interim Dividend |
09-08-2022 | Interim Dividend & Quarterly Results |
30-05-2022 | Audited Results |
14-02-2022 | Third Interim Dividend & Quarterly Results |
11-11-2021 | Quarterly Results & Interim Dividend |
12-08-2021 | Quarterly Results & Interim Dividend |
17-06-2021 | Interim Dividend & Audited Results |